Back to results
US 2020/0263145 A1Published application
Recombinant vaccinia virus and methods of use thereof
AssigneeIgnite Immunotherapy, Inc.
InventorsDavid H. Kirn, Liliana Maruri Avidal, Prajit Limsirichai
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a replication-competent, recombinant oncolytic vaccinia virus, compositions comprising the vaccinia virus, and use of the vaccinia virus or composition for inducing oncolysis in an individual having a tumor.
Claims27
A replication-competent, recombinant oncolytic vaccinia virus comprising a nucleotide sequence encoding a heterologous thymidine kinase (TK) polypeptide, wherein the heterologous TK polypeptide is capable catalyzing phosphorylation of deoxyguanosine.
(canceled)
(canceled)
17-32. (canceled)
(canceled)
36-40. (canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.